Trial Profile
A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN #1203; Progress I)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Maraviroc (Primary) ; Methotrexate (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms Progress I
- 05 Apr 2018 Status changed from active, no longer recruiting to completed.
- 16 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2014 New trial record